

State of Oklahoma SoonerCare Xtandi[®] (Enzalutamide) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	on
Pharmacy billing (NDC:) Start Date (or date of next dose):	
Dose:	Regimen:	
Billing Provider Information		
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fax:	
Prescriber Information		
Prescriber NPI:	ber NPI: Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
☐ Metastatic castrati☐ Non-metastatic ca1. Is biochemical☐ Other:	nt prostate cancer (CRPC) on-sensitive prostate cancer (C stration-sensitive prostate cancer recurrence at high risk for meta	er estasis (high-risk BCR)? Yes No
1. Date of last dose:		
 Does patient have any evidence of progressive disease while on enzalutamide therapy? Yes \(\subseteq \) No \(\subseteq \) 		
3. Has the member experient Yes No	nced any adverse drug reaction	s related to enzalutamide therapy?
If yes, please specify advers	e reactions:	
Prescriber Signature:_		_ Date:
I certify that the indicated to correct to the best of my ke Please do not send in chart i	treatment is medically necess nowledge.	sary and all information is true and be requested if necessary. Failure to

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm-55 12/8/2023